CSI Diamondback 360 Coronary Orbital Atherectomy System, 1.25mm, Classic
In Stock: 26 Eaches
Express: Need it tomorrow? Order in next 2 hours 8 minutes and choose overnight shipping at checkout.
The item listed above is expired and may be used for educational, training, and non-clinical research purposes only. Any product information appearing below, including the product indication statement, pertains to an in-date item only.
Description
CSI Diamondback 360®
DBEC-125
- Coronary Orbital Atherectomy System
- Crown Size: 1.25mm
- Crown Style: Classic
- Shaft Length: 135cm
- Nose Length: 5mm
Additional information
| Size | 1 |
|---|---|
| Arms | N/A |
| Manufacturer | |
| Type | Atherectomy |
| Unit | box of 1 |
- FDA Product Code: MCX
- FDA Product Code Name: Catheter, Coronary, Atherectomy
- GMDN Term Code: 61205
- GMDN Term Name: Mechanical atherectomy system, coronary, line-powered
- GMDN Term Description: An assembly of devices intended to mechanically disrupt/remove atheroma plaque from the walls of coronary arteries. It typically includes a mains electricity (AC-powered) energy-producing generator with monitoring functions, a remote control or foot-switch, a handpiece (to which the catheter connects) and a dedicated disposable catheter with a cutting or abrasive head that transmits the mechanical energy to the atheroma. The system may include an integrated irrigation/suction system and includes/requires accessory devices for its function (e.g., saline/lubricant, pump, guidewire).
CSI
Cardiovascular Systems, Inc. (CSI), now a part of Abbott, specialized in innovative solutions for the treatment of peripheral and coronary artery disease through its proprietary orbital atherectomy systems. CSI’s flagship technologies include the Diamondback 360® Peripheral Orbital Atherectomy System and the Diamondback 360® Coronary Orbital Atherectomy System, both designed to modify calcified plaque and improve vessel compliance prior to stent placement or balloon angioplasty.
These systems use a diamond-coated crown that orbits within the vessel, sanding away plaque while preserving healthy tissue and facilitating better device delivery. CSI’s focus on challenging arterial disease—particularly in heavily calcified lesions—made it a valuable addition to Abbott’s vascular portfolio following its acquisition in 2023, further expanding minimally invasive treatment options for complex cardiovascular cases.
